The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...

Using artificial intelligence (AI), researchers looked at brain scans and tested for a blood marker for nerve cell injury and ...

Researchers say the more they find out, the more likely 'we will be able to find treatments that can stop disease progression ...

That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...

Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help ...

Scientists from UCL have used artificial intelligence to discover two new biological sub-types of multiple sclerosis ...

Cortez, whose rise to prominence foreshadowed Zohran Mamdani’s success, will speak at his swearing-in outside City Hall on ...